Literature DB >> 9454652

The impact of adjuvant radiotherapy on carcinosarcoma of the uterus.

K Gerszten1, C Faul, S Kounelis, Q Huang, J Kelley, M W Jones.   

Abstract

BACKGROUND: The role of adjuvant radiotherapy in the setting of uterine carcinosarcoma has not been clearly established.
METHODS: A retrospective review of 60 patients receiving definitive therapy for carcinosarcoma of the uterus was undertaken at a single institution. Twenty-nine of 60 patients were treated with adjuvant radiotherapy.
RESULTS: The addition of radiotherapy significantly reduced the local recurrence rate from 55% (17 patients) to 3% (1 patient). Adjuvant radiotherapy reduced the risk of distant failure and death in patients with disease confined to the uterus but did not impact distant recurrence or survival in stage III patients. Increasing stage and depth of myometrial tumor invasion were negatively associated with overall survival and disease-free survival but had no impact on local recurrence rates. The nuclear grade of the epithelial component was predictive of local recurrence (P = 0.0592), but epithelial architectural grade, grade of stromal component, and stromal versus epithelial predominance did not provide prognostic information. The relative risk of local recurrence of unirradiated patients versus irradiated patients was 17.54 (P = 0.0055) after adjusting for nuclear grade of the epithelial component.
CONCLUSIONS: Local failure represents a significant site of failure in the absence of adjuvant radiotherapy. The improvement in local failure rates with the addition of radiotherapy translates into an improvement in distant failure rates and survival only for patients with stage I/II disease. Epithelial nuclear grade, in addition to depth of myometrial invasion and stage, provides important prognostic information. Epithelial architectural grade, stromal grade, type of stromal component (homologous versus heterologous), and predominance of either stromal or epithelial component were not found to be significant prognostic factors. Copyright 1998 Academic Press.

Entities:  

Mesh:

Year:  1998        PMID: 9454652     DOI: 10.1006/gyno.1997.4901

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

2.  Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.

Authors:  Mark H Einstein; Merieme Klobocista; June Y Hou; Stephen Lee; Subhakar Mutyala; Keyur Mehta; Laura L Reimers; Dennis Y-S Kuo; Gloria S Huang; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2011-11-03       Impact factor: 5.482

3.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

Review 4.  Uterine sarcoma 2008.

Authors:  Jeff F Lin; Brian M Slomovitz
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

5.  The reasonable timing of the adjuvant radiotherapy in the treatment of uterine carcinosarcoma according to the surgical intent: suggestion based on progression patterns.

Authors:  Jeong Il Yu; Doo Ho Choi; Seung Jae Huh; Won Park; Dongryul Oh; Duk Soo Bae
Journal:  Radiat Oncol J       Date:  2013-06-30

6.  Uterine carcinosarcomas: 8-year single center experience of 25 cases.

Authors:  Kalpana S Dave; Anjana Chauhan; Ronak Bhansali; Ruchi Arora; Sushma Purohit
Journal:  Indian J Med Paediatr Oncol       Date:  2011-07

7.  Outcome analysis in patients with uterine sarcoma.

Authors:  Tosol Yu; Hak Jae Kim; Hong-Gyun Wu; Sung Whan Ha; Yong-Sang Song; Noh-Hyun Park; Jae-Won Kim
Journal:  Radiat Oncol J       Date:  2015-03-31

8.  Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report.

Authors:  P Martin-Romano; M Jurado; M A Idoate; L Arbea; J L Hernandez-Lizoain; D Cano; J A Paramo; S Martin-Algarra
Journal:  J Med Case Rep       Date:  2017-04-19

9.  Uterine mullerian adenosarcoma with sarcomatous overgrowth fatal recurrence within two weeks of diagnosis: a case report.

Authors:  Mirna H Farhat; Elie M Hobeika; Ghada Moumneh; Anwar H Nassar
Journal:  J Med Case Rep       Date:  2007-09-25

Review 10.  Carcinosarcoma of the corpus uteri (Malignant Müllerian Mixed Tumor): a case report in Yaoundé (Cameroon).

Authors:  Zacharie Sando; Florent Ymele Fouelifack; Jovanny Tsuala Fouogue; Jeanne Hortence Fouedjio; Chimene Etonga Anoudem; Charlette Nangue
Journal:  Pan Afr Med J       Date:  2013-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.